search icon
rna-img

Atrium Therapeutics, Inc. Common Stock Share Price

RNA
NASDAQ
$14.91
+$0.16
(1.08%)
1D
Industry: Biotechnology Sector: Health Care

Atrium Therapeutics, Inc. Common Stock Analyst Forecast

Atrium Therapeutics, Inc. Common Stock Share Price Chart

Atrium Therapeutics, Inc. Common Stock Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.28B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
3.21M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.93
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$13.06 L
$73.06 H
$14.91

About Atrium Therapeutics, Inc. Common Stock, Common Stock

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in clinical development, such as Delpacibart zotadirsen which is in Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy; Delpacibart etedesiran which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; and Delpacibart braxlosiran that is in Phase 1/2 development stage for the treatment of facioscapulohumeral muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Atrium Therapeutics, Inc. Common Stock Stock Returns

Time FrameRNASectorS&P500
1-Week Return-79.55%1.05%0.54%
1-Month Return-79.5%2.9%-1.35%
3-Month Return-79.16%3.78%0.71%
6-Month Return-68.43%16.46%7.19%
1-Year Return-48.97%7.1%17.53%
3-Year Return-37.22%25.41%72.66%
5-Year Return-42.05%40.84%77.58%
10-Year Return-47.68%136.42%245.74%

Atrium Therapeutics, Inc. Common Stock Financials

Dec '21Dec '22Dec '23Dec '24Dec '255YR TREND
Total Revenue9.33M9.22M9.56M10.90M18.75M[{"date":"2021-12-31","value":49.73,"profit":true},{"date":"2022-12-31","value":49.18,"profit":true},{"date":"2023-12-31","value":50.97,"profit":true},{"date":"2024-12-31","value":58.1,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Cost of Revenue639.00K1.39M2.10M2.78M4.15M[{"date":"2021-12-31","value":15.39,"profit":true},{"date":"2022-12-31","value":33.41,"profit":true},{"date":"2023-12-31","value":50.61,"profit":true},{"date":"2024-12-31","value":66.88,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Gross Profit9.33M9.22M7.46M10.90M14.60M[{"date":"2021-12-31","value":63.86,"profit":true},{"date":"2022-12-31","value":63.16,"profit":true},{"date":"2023-12-31","value":51.08,"profit":true},{"date":"2024-12-31","value":74.62,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Gross Margin100.00%100.00%78.02%100.00%77.87%[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":78.02,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":77.87,"profit":true}]
Operating Expenses127.38M188.14M243.06M389.83M760.55M[{"date":"2021-12-31","value":16.75,"profit":true},{"date":"2022-12-31","value":24.74,"profit":true},{"date":"2023-12-31","value":31.96,"profit":true},{"date":"2024-12-31","value":51.26,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Operating Income(118.05M)(178.91M)(235.60M)(378.94M)(745.94M)[{"date":"2021-12-31","value":-11805100000,"profit":false},{"date":"2022-12-31","value":-17891300000,"profit":false},{"date":"2023-12-31","value":-23559800000,"profit":false},{"date":"2024-12-31","value":-37893600000,"profit":false},{"date":"2025-12-31","value":-74594300000,"profit":false}]
Total Non-Operating Income/Expense146.00K9.89M43.72M113.52M-[{"date":"2021-12-31","value":0.13,"profit":true},{"date":"2022-12-31","value":8.72,"profit":true},{"date":"2023-12-31","value":38.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Pre-Tax Income(118.01M)(174.00M)(212.22M)(322.30M)(684.63M)[{"date":"2021-12-31","value":-11800900000,"profit":false},{"date":"2022-12-31","value":-17399500000,"profit":false},{"date":"2023-12-31","value":-21222000000,"profit":false},{"date":"2024-12-31","value":-32230200000,"profit":false},{"date":"2025-12-31","value":-68463100000,"profit":false}]
Income Taxes(639.00K)(4.92M)1.93M--[{"date":"2021-12-31","value":-33.06,"profit":false},{"date":"2022-12-31","value":-254.41,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Income After Taxes(117.37M)(169.08M)(214.15M)--[{"date":"2021-12-31","value":-11737000000,"profit":false},{"date":"2022-12-31","value":-16907700000,"profit":false},{"date":"2023-12-31","value":-21415310500,"profit":false},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Income From Continuous Operations(118.01M)(174.00M)(202.25M)(322.30M)(76.68M)[{"date":"2021-12-31","value":-11800900000,"profit":false},{"date":"2022-12-31","value":-17399500000,"profit":false},{"date":"2023-12-31","value":-20224800000,"profit":false},{"date":"2024-12-31","value":-32230200000,"profit":false},{"date":"2025-12-31","value":-7668400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Net Income(117.37M)(169.08M)(212.22M)(322.30M)(684.63M)[{"date":"2021-12-31","value":-11737000000,"profit":false},{"date":"2022-12-31","value":-16907700000,"profit":false},{"date":"2023-12-31","value":-21222000000,"profit":false},{"date":"2024-12-31","value":-32230200000,"profit":false},{"date":"2025-12-31","value":-68463100000,"profit":false}]
EPS (Diluted)(2.84)(3.33)(2.90)(2.89)(4.97)[{"date":"2021-12-31","value":-284,"profit":false},{"date":"2022-12-31","value":-333,"profit":false},{"date":"2023-12-31","value":-290,"profit":false},{"date":"2024-12-31","value":-289,"profit":false},{"date":"2025-12-31","value":-497,"profit":false}]

Atrium Therapeutics, Inc. Common Stock Ratios

Atrium Therapeutics, Inc. Common Stock Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

RNA
Cash Ratio 8.68
Current Ratio 9.20

Atrium Therapeutics, Inc. Common Stock Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RNA
ROA (LTM) -26.48%
ROE (LTM) -43.98%

Atrium Therapeutics, Inc. Common Stock Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RNA
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Atrium Therapeutics, Inc. Common Stock Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RNA
Trailing PE NM
Forward PE NM
P/S (TTM) 599.63
P/B 5.40
Price/FCF NM
EV/R 491.01
EV/Ebitda NM
PEG NM

FAQs

What is Atrium Therapeutics, Inc. Common Stock share price today?

Atrium Therapeutics, Inc. Common Stock (RNA) share price today is $14.91

Can Indians buy Atrium Therapeutics, Inc. Common Stock shares?

Yes, Indians can buy shares of Atrium Therapeutics, Inc. Common Stock (RNA) on Vested. To buy from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RNA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Atrium Therapeutics, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of Atrium Therapeutics, Inc. Common Stock (RNA) via the Vested app. You can start investing in Atrium Therapeutics, Inc. Common Stock (RNA) with a minimum investment of $1.

How to invest in Atrium Therapeutics, Inc. Common Stock shares from India?

You can invest in shares of Atrium Therapeutics, Inc. Common Stock (RNA) via Vested in three simple steps:

  • Click on Sign Up or Invest in RNA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Atrium Therapeutics, Inc. Common Stock shares
What is Atrium Therapeutics, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of Atrium Therapeutics, Inc. Common Stock (RNA) is $73.06. The 52-week low price of Atrium Therapeutics, Inc. Common Stock (RNA) is $13.06.

What is Atrium Therapeutics, Inc. Common Stock price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Atrium Therapeutics, Inc. Common Stock (RNA) is

What is Atrium Therapeutics, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Atrium Therapeutics, Inc. Common Stock (RNA) is 5.40

What is Atrium Therapeutics, Inc. Common Stock dividend yield?

The dividend yield of Atrium Therapeutics, Inc. Common Stock (RNA) is 0.00%

What is the Market Cap of Atrium Therapeutics, Inc. Common Stock?

The market capitalization of Atrium Therapeutics, Inc. Common Stock (RNA) is $2.28B

What is Atrium Therapeutics, Inc. Common Stock's stock symbol?

The stock symbol (or ticker) of Atrium Therapeutics, Inc. Common Stock is RNA

How Can Investors Use Atrium Therapeutics, Inc. Common Stock Share Price Data for Long-Term Investment Decisions?

Consider the share price of Atrium Therapeutics, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Atrium Therapeutics, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Atrium Therapeutics, Inc. Common Stock shares for Indian investors?

When investing in Atrium Therapeutics, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Atrium Therapeutics, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Atrium Therapeutics, Inc. Common Stock share price with other stocks in the same sector?

Rather than merely checking the share price of Atrium Therapeutics, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Atrium Therapeutics, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top